Laura is the editorial director of The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®'s parent company, MJH Life Sciences, since 2011. She has an MA in business and economic reporting from New York University.
A better understanding of the genetic etiology of pulmonary arterial hypertension and its molecular variants is needed to develop better therapies for the disease, which has no agents available that can reverse or halt it.
Pulmonary arterial hypertension (PAH) has remained a fatal disease with no pharmacological agents available to reverse or halt the disease. As there is no cure, there is an unmet need to understand the genetic etiology of PAH and molecular variants in order to develop better novel therapies.
A study published in The Application of Clinical Genetics identifies potential mutations that are responsible for PAH.
“…A number of potentially causative mutations in genes primarily related to PAH as well as genetic and epigenetic modifiers of disease expression have been discovered via advanced genetic and genomic techniques including but not limited to conventional linkage analysis and next-generation sequencing technologies,” the authors explained.
In familial cases of PAH, not all individuals at risk are affected, and women are preferentially affected in an approximate 2:1 ratio. While 6% of PAH cases are heritable PAH (HPAH), this may be an underestimate, as cases of HPAH may be misclassified as idiopathic PAH (IPAH).
In 75% of HPAH and 20% of IPAH cases, mutations in the gene encoding bone morphogenetic protein receptor type 2 (BMPR2) may be responsible. Compared with patients without the mutation, patients with PAH who have the BMPR2 mutation are not only diagnosed and die 10 years earlier, but they also are less likely to benefit from calcium channel blockers.
BMPR2 mutations are a member of the transforming growth factor-beta (TGF-β) receptor superfamily. The researchers noted that approximately 20% of families with HPAH do not have detectable mutations along this pathway.
“This has led the scientific community to search for additional mutations which may contribute to PAH pathobiology,” they explained. Other genes include:
Targeting molecular pathways that may contribute to PAH could provide new approaches to treat the disease. The 6th World Symposium on Pulmonary Hypertension task force recommends genetic screening even though there is no prevention or cure for PAH. However, identifying heritable disease could allow for closer monitoring, earlier disease detection, and earlier initiation of therapy.
“As genetic and other types of inherent biologic variations rarely occur in isolation, major advancements can be expected in the next few years in the identification of additional genes as well as genetic and environmental modifiers for PAH,” the authors concluded. “Larger genetic and biomarkers studies, with a close interplay of animal and human approaches will be necessary to better understand the complex genetic networks and events that promote PAH in genetically at-risk subjects.”
Eroume-A Egom E, Moyou-Somo R, Essame Oyono JL, Kamgang R. Identifying potential mutations responsible for cases of pulmonary arterial hypertension. Appl Clin Genet. 2021;14:113-124. doi:10.2147/TACG.S260755